Understanding the Melanoma Market Landscape: A Closer Look at the Current Trends and Future Market Dynamics

REGISTER TODAY

Wed 22 Apr 2015 – 10:00 AM   Eastern Daylight Time (GMT-4)
45 minutes session

After being stagnant for many years, the melanoma branded market has now become one of the fastest-growing markets among all major cancer indications since the approval of Bristol-Myers Squibb’s (BMS’) Yervoy (ipilimumab) and Roche’s Zelboraf (vemurafenib) in 2011. In 2014, BMS’ Opdivo (nivolumab), Merck’s Keytruda (pembrolizumab) and GlaxoSmithKline’s (GSK’s) (now Novartis’) Tafinlar/Mekinist (dabrafenib/trametinib) combination joined the blooming market of melanoma. These immune checkpoint inhibitors and BRAF/MEK inhibitors are expected to take up more than 97% of the melanoma market. The pipeline for melanoma remains strong, with seven new agents in Phase III development. In addition, companies are focusing on the development of novel drug combinations and label expansion of existing therapeutics.

Over GlobalData’s 2013–2023 forecast period, the increased uptake of anti-PD-1 immunotherapies and BRAF/MEK inhibitor combinations is expected to drive market growth, while limited opportunities for new entrants in the eight major markets  (US, France, Germany, Italy, Spain, UK, Japan, and Australia) are projected to curtail growth.

Join this webinar to increase your knowledge of the current state of the melanoma market and what can be expected in this exciting therapeutic area in the future. Dr. Valentina Gburcik, GlobalData’s Therapy Director covering Cardiovascular & Metabolic Disorders, will moderate a Q&A session following the presentation, please send your questions in advance to [email protected].  

REGISTER TODAY